2012•Clinical Lymphoma Myeloma & LeukemiaOpen access

Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia

Elias Joseph Jabbour, Guillermo Garcia‐Manero, Jörge E. Cortes, Farhad Ravandi, William K. Plunkett, Varsha V. Gandhi, Stefan H Faderl, Susan O’Brien, Gautam M. Borthakur, Tapan Mahendra Kadia, Jan A. Burger, Marina Y Konopleva, Mark Brandt, Xuelin Huang, Hagop M. Kantarjian

Open full text 36 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 36 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Myeloid leukemia, Cytarabine, Fludarabine, Internal medicine, Gemtuzumab ozogamicin, Myelodysplastic syndromes, Gastroenterology